DMAC vs. KMPH, ESPR, ERAS, NGNE, VERV, FBLG, LXRX, TBPH, CTNM, and SLRN
Should you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Zevra Therapeutics (KMPH), Esperion Therapeutics (ESPR), Erasca (ERAS), Neurogene (NGNE), Verve Therapeutics (VERV), FibroBiologics (FBLG), Lexicon Pharmaceuticals (LXRX), Theravance Biopharma (TBPH), Contineum Therapeutics (CTNM), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical preparations" industry.
DiaMedica Therapeutics (NASDAQ:DMAC) and Zevra Therapeutics (NASDAQ:KMPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.
DiaMedica Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500.
Zevra Therapeutics has higher revenue and earnings than DiaMedica Therapeutics.
Zevra Therapeutics received 255 more outperform votes than DiaMedica Therapeutics when rated by MarketBeat users. Likewise, 63.07% of users gave Zevra Therapeutics an outperform vote while only 62.07% of users gave DiaMedica Therapeutics an outperform vote.
In the previous week, DiaMedica Therapeutics had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 2 mentions for DiaMedica Therapeutics and 0 mentions for Zevra Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.44 beat Zevra Therapeutics' score of 0.00 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.
DiaMedica Therapeutics has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -328.56%. Zevra Therapeutics' return on equity of -16.12% beat DiaMedica Therapeutics' return on equity.
DiaMedica Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 141.38%.
10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 19.4% of Zevra Therapeutics shares are owned by institutional investors. 7.2% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 1.1% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Zevra Therapeutics beats DiaMedica Therapeutics on 8 of the 13 factors compared between the two stocks.
Get DiaMedica Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DiaMedica Therapeutics Competitors List
Related Companies and Tools
